Laura Schuettpelz

Specialized Program of Research Excellence (SPORE) in Leukemia

National Cancer Institute · P50

Project lead · $376K · Washington University

Modeling TLR8 Gain of Function Disease

National Institute of Allergy and Infectious Diseases · R21

Contact PI · $233.3K · Washington University

Defining the Partner Interaction Network of the Tetraspanin CD53 in Regulating B Cell Trafficking

National Institute of Allergy and Infectious Diseases · R01

Contact PI · $2.8M · Washington University

Pediatric Training Program Hematology and Oncology

National Cancer Institute · T32

Contact PI · $271.9K · Washington University

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Site PI · Recruiting · Phase 2

National Cancer Institute (NCI)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Site PI · Recruiting · Phase 2

National Cancer Institute (NCI)

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Site PI · Recruiting · Phase 1, Phase 2

PedAL BCU, LLC